Pharmacolog signs a collaboration agreement with researchers at Uppsala University regarding antibiotic treatment

Pharmacolog AB has entered a research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood during treatment of patients with severe infections.

Antibiotic treatment with the right dose is crucial for patients to survive severe infections. Today, technology is lacking to quickly determine blood concentrations of antibiotics in patients treated for serious infections. The collaboration between Pharmacolog AB and Professor Miklos Lipcsey at the Department of Surgical Sciences and Professor Anders Larsson at the Department of Medical Sciences, both at Uppsala University, is a result of preparatory tests of the ability to measure the antibiotic concentration in blood with Pharmacolog’s current technology. The collaboration will continue until December 2017 with the aim of developing a method for rapidly and patiently determining blood levels of antibiotics in patients treated for severe infections.

Hans Dahlin, Founder and Research Director at Pharmacolog: “I am extremely pleased that after a time of preliminary tests we can start this important research project with two outstanding experts on antibiotic treatment of severe infections. The project is well within our vision of participating in research projects that can lead to the development of new products for patient-controlled controls of intravenous drug treatments of severe diseases such as sepsis and cancer.”

Dr. Miklos Lipcsey, anesthetist and researcher Academic Hospital: “Healthcare is facing major challenges regarding the use of antibiotics. The correct dose is necessary to cure difficult infections but also a prerequisite for preventing resistance development. The research collaboration with Pharmacolog is very interesting given the great need for rapid analysis and measures in the treatment of antibiotics in severe infections. Several studies have shown that delayed or insufficient initial antibiotic treatment leads to significantly increased mortality in sepsis. We have already received some interesting promising results that we now hope through this project will result in scientific work that can contribute to new products for safer and more patient-adapted antibiotic treatment.”


Offentliggörande av prospekt

Pharmacolog i Uppsala AB (publ) offentliggör prospekt för beslutad företrädesemission med teckningsperiod 27 september – 13 oktober 2017.

Styrelsen för Pharmacolog i Uppsala AB (”Pharmacolog”) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för Pharmacologs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen. Prospekt, innehållande fullständiga villkor och anvisningar, samt anmälningssedlar kommer att finnas att tillgå på Pharmacologs ( ), AktieTorgets ( ) och Erik Penser Banks ( ) respektive hemsidor. Emissionen i sammandrag

Aktieägare i Pharmacolog har företrädesrätt ...

Pharmacolog signs a letter of intent on cooperation with major international Medtech Group

Pharmacolog AB has signed a letter of intent with a company that is part of a large global group to engage in long-term cooperation aimed at integrating Pharmacolog’s technology into the company’s system for safe and efficient handling of chemotherapy at pharmacies and healthcare departments.

The letter of intent entails that the parties work to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare departments.

Mats Högberg CEO of Pharmacolog comments: “We have conducted a targeted effort to establish strategic partnerships with maj...

Pharmacolog säkerställer fortsatt finansiering genom företrädesemission

Styrelsen i Pharmacolog har beslutat genomföra en nyemission om 19,6 miljoner kronor med företräde för bolagets befintliga aktieägare. Villkoren i nyemissionen innebär att en (1) befintlig aktie ger rätt att teckna en (1) ny aktie till kursen 5,00 kronor per aktie. Vid full teckning tillförs Pharmacolog 19,6 miljoner kronor före emissionskostnader. Teckningstiden löper från och med den 27 september till och med den 13 oktober 2017. Emissionen omfattas till omkring 83 procent av teckningsåtaganden och garantiutfästelser.

Styrelsen i Pharmacolog i Uppsala AB (publ) (”Bolaget” eller ”Pharmacolog”) beslutade den 28 augusti 2017, med stöd av bemyndigande lämnat vid årsstämman den 3 maj 2017, att genom...

Successful collaboration with Swedish university hospital enters the next phase

Pharmacolog has, in collaboration with one of the leading university hospitals in Sweden, developed ARM (Advanced Reconstruction Module). The system will be tested in clinical environments for 6 months and comprises 2 DrugLog systems that will be rented during the project period.

Astrid Lindgren’s Children’s Hospital at Karolinska University Hospital will with funding from SLL Innovation to undertake a 6-month project to test the Advanced Reconstruction Module (ARM) with its associated DrugLog® in a clinical environment. The project runs throughout the year and includes the lease of two DrugLog systems.

The ARM, partly funded by Vinnova, was implemented during the second half o...